People who base their health choices on what they found on the internet instead of talking to their doctors have long since been regarded with a generous amount of disdain. However, a new study suggests that using web-based counseling is actually just as effective at lowering blood pressure as taking actual medication.
The study was presented during the 66th Annual Scientific Session and Expo, which was held in Washington, D.C., The Washington Post reports. It looked at the cases of patients who enrolled in the website Heart and Stroke Association of Canada, where over 264 people diagnosed with high blood pressure and with an average age of 56 years old were tracked.
The groups were divided based on Web-based lifestyle counseling and Web-based control intervention, both of which involved different approaches to addressing systolic blood pressure. It would seem that the former method yielded better results than the latter, but both systems did accomplish the goal of reducing mmHg levels in the patients.
Robert P. Nolan from the Peter Munk Cardiac Center at the University Health Network is the lead author of the study and he calls web-based counseling e-Counseling. He confirmed that this method had similar results compared to having the patients take drugs in order to control their blood pressure.
“The electronic counseling (e-Counseling) intervention had an effect similar to that of adding an additional blood-pressure-lowering medication,” Prof. Nolan said.
As to what this so-called e-Counseling even involves, patients are given a variety of resources in order to help them cope with their health condition. These include interactive online content, as well as a few video and audio resources, MedicalXpress reports. Based on the results that the researchers got from the study, it would seem that the more engaging content yielded the best improvements in lowering blood pressure among the patients.


Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone
U.S.-China AI Talks May Take Center Stage at Trump-Xi Summit
Anthropic Eyes $300M Stainless Acquisition Amid Enterprise AI Expansion
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes
Samsung Shares Slide as Wage Talks Collapse, Raising Strike Fears
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers 



